丰加霉素在内质网应激中的研究进展及与抗肿瘤相关机制研究
| 作者: |
1田启泽,
1胡瑞成,
1戴爱国
1 南华大学附属省马王堆医院呼吸内科；湖南省老年医院呼吸疾病研究所，长沙 410016 |
| 通讯: |
胡瑞成
Email: huruicheng@hotmail.com |
| DOI: | 10.3978/j.issn.2095-6959.2016.02.017 |
摘要
丰加霉素(Toyocamycin)是一种嘌呤核苷类似物，最早在链霉菌培养基中被发现，能影响多种原核生物及真核生物的生长代谢，具有抗菌、抗病毒、抗寄生虫以及抗肿瘤的作用。由于其具有较强的毒性作用，因此临床应用受限。最近研究发现丰加霉素与内质网应激密切相关，通过干扰未折叠蛋白反应过程而起到显著的抗肿瘤作用，提示丰加霉素在抗肿瘤方面有望出现新的进展，本文就丰加霉素作用机制方面的研究及其进展综述如下。
关键词：
丰加霉素
内质网应激
未折叠蛋白反应
肿瘤
抗生素
凋亡
The research progress about the role of toyocamycin in the ERS and its antitumor mechanism
CorrespondingAuthor: HU Ruicheng Email: huruicheng@hotmail.com
DOI: 10.3978/j.issn.2095-6959.2016.02.017
Abstract
Toyocamycin is a purine nucleoside analogue and first to be discovered in streptomyces medium. Toyocamycin can affect the growth of a variety of prokaryotes and eukaryotes; it has significant anti-bacterial, anti-viral, anti-parasitic and anti-tumor effects. Because of its strong toxicity, the clinical application of toyocamycin was limited. However, recent studies have found that toyocamycin was closely associated with endoplasmic reticulum stress, and it could kill tumor by interfering the UPR process, while the mechanism is different from previous, suggesting that the role of toyocamycin in antitumor may have a new development. This thesis will review the mechanism of toyocamycin and its developments.